Calcific uraemic arteriolopathy: an update (2008 study) Skip to main content
Review Curr Opin Nephrol Hypertens 2008

Calcific uraemic arteriolopathy: an update

Rogers N, Coates P, Curr Opin Nephrol Hypertens, 2008

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

The authors reviewed recent research on calcific uraemic arteriolopathy (also called calciphylaxis), a rare condition in people with chronic kidney disease, and the treatments being used for it.

What They Found

This narrative review of calcific uraemic arteriolopathy found that the condition is a rare but important cause of illness and death in people with chronic kidney disease, and that its prevalence is increasing in patients with renal failure. The condition is also being recognized in people without kidney failure. The review describes growing understanding of how blood vessel calcification happens, including the role of the uraemic microenvironment in turning vascular smooth muscle cells into bone-forming cells. Newer treatments for high phosphate and secondary hyperparathyroidism, including bisphosphonates, newer phosphate binders and case reports of cinacalcet, have begun to be used in these patients. The abstract also lists hyperbaric oxygen and sodium thiosulphate as other treatments not aimed directly at calcium and phosphate balance.

What This Means for Canadian Patients

For people with calciphylaxis, the review suggests clinicians should consider combining newer drugs that treat calcium and phosphate problems with older approaches for promoting wound healing, such as hyperbaric oxygen and sodium thiosulphate infusions. The abstract does not give a session number, pressure or results for hyperbaric oxygen, so it does not show how well it works. Patients should talk with their kidney care team about which options fit their situation.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

The abstract states that randomized controlled trials for treatments in this condition are still lacking, and it mentions cinacalcet only as case reports, so the treatment suggestions are not backed by controlled trial evidence.

This plain-language summary was generated with AI assistance from the study's abstract; it has not been individually reviewed by a clinician. Always consult the source study and a qualified healthcare professional. See our editorial policy.

Was this summary helpful?

Study Details

Study Type Review
Category Systematic Reviews
Source Pubmed
PubMed ID 18941358
Year Published 2008
Journal Curr Opin Nephrol Hypertens
MeSH Terms Calciphylaxis; Calcium; Chelating Agents; Chronic Disease; Humans; Hyperbaric Oxygenation; Kidney Diseases; Phosphates; Risk Factors; Thiosulfates; Treatment Outcome; Uremia; Vascular Diseases

Cite This Study

Share

Find a Canadian Clinic

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last updated: April 17, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology